Search results
Results from the WOW.Com Content Network
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. [ 5 ] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication .
Treating a dog's arthritis is often challenging because many dogs don't show signs of pain until they're older, vets said. After the condition has progressed to severe levels, owners often feel ...
Imetelstat, if approved, will be Geron's first commercial treatment in the market and will compete with Bristol Myers Squibb's Reblozyl, which received a label expansion by the FDA last year for ...
A myelodysplastic syndrome (MDS) is one of a group of cancers in which blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. [3] Early on, no symptoms typically are seen. [3] Later, symptoms may include fatigue, shortness of breath, bleeding disorders, anemia, or frequent infections. [3]
These symptoms may persist or occur periodically and if symptoms are not managed, major complications may develop including permanent joint changes, chronic pain, and functional disabilities. [7] Ultimately, antiarthritic treatments aim to achieve disease remission or low disease activity if remission cannot be achieved and thereby improving ...
A popular arthritis medication for dogs has sickened thousands of pets and likely caused others to die, the Food and Drug Administration said in an urgent warning. Dangerous side effects from the ...
Weight control is often "the single most important thing that we can do to help a dog with arthritis," and "reducing the dog's weight is enough to control all of the symptoms of arthritis in many dogs." [14] With weight control, the goal is to prevent the dog from becoming overweight to reduce mechanical stresses applied to the hip joints. In ...
(Reuters) -The U.S. Food and Drug Administration's staff reviewers said on Tuesday they were unclear if Geron's blood disorder drug provided a clear benefit to patients in a late-stage trial and ...